RETATRUTIDE (30mg)

This 30mg presentation of retatrutide supports extended research protocols or investigations requiring higher cumulative compound availability. Retatrutide's triple agonism of GLP-1, GIP, and glucagon receptors continues to set new benchmarks in obesity pharmacology research, with Phase 2 data reporting weight reductions of up to 24% of body weight.

Mechanism of Action

•        Simultaneous GLP-1, GIP, and glucagon receptor activation drives complementary metabolic benefits in research models.

•        GLP-1/GIP agonism studied for appetite modulation and glycemic control; glucagon agonism investigated for caloric expenditure and hepatic fatty acid oxidation.

•        Research shows comprehensive visceral and hepatic fat reduction through multi-pathway metabolic modulation.

Research Areas

•        Advanced obesity pharmacology research requiring extended study supply.

•        Multi-cycle weight loss and plateau management studies.

•        NAFLD/NASH biology combined with metabolic syndrome research.

Presentation and Storage

Supplied as a lyophilized powder in a sealed vial containing 30mg of retatrutide. Reconstitute with bacteriostatic water for laboratory use. Store at -20C.